Apollo Hospitals Enterprise Limited vs Samrat Pharmachem Ltd

A side-by-side comparison of Apollo Hospitals Enterprise Limited (APOLLOHOSP) and Samrat Pharmachem Ltd (SAMRATPH) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Apollo Hospitals Enterprise Limited leads APOLLOHOSP vs SAMRATPH on 9 of 14 metrics (1 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation13
  • Profitability40
  • Growth10
  • Size & financial health31

Valuation

SAMRATPH takes 3/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

57.02
P/E ratio
-32.40
13.46
P/B ratio
1.05
0.22%
Dividend yield
0.43%
₹135.04
EPS
₹-10.72

Profitability

APOLLOHOSP takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

20.48%
Return on equity
-4.86%
17.31%
Return on capital
-2.57%
14.94%
EBITDA margin
-0.74%
7.94%
Net margin
-1.14%

Growth

APOLLOHOSP takes 1/2

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

14.94%
Revenue CAGR (3Y)
-2.33%
33.35%
Profit CAGR (3Y) even
—

Size & financial health

APOLLOHOSP takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹1.11L Cr
Market cap
₹83 Cr
₹25,229 Cr
Revenue
₹290 Cr
₹2,003 Cr
Net profit
₹-3 Cr
0.90
Debt / equity
0.16
Apollo Hospitals Enterprise Limited
  • + ["Company has delivered good profit growth of 71.1% CAGR over last 5 years", "Company has delivered good sales growth of 19.0% CAGR over last 5 years"]
  • − ["Stock is trading at 11.68 times its book value"]
Samrat Pharmachem Ltd
  • + []
  • − ["Company has a low return on equity of 3.0% over last 3 years.", "Company reported a net loss of ₹3 Cr in its latest financial year."]
Apollo Hospitals Enterprise Limited full analysis Samrat Pharmachem Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.